Does ambulatory oxygen improve quality of life in patients with fibrotic lung disease? Results from the AmbOx trial

Breathe (Sheff). 2019 Jun;15(2):140-143. doi: 10.1183/20734735.0002-2019.

Authors

Andrew W Creamer¹, Shaney L Barratt²

Affiliations

¹ Respiratory Medicine, North Bristol NHS Trust, Westbury on Trym, UK.
² Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Westbury on Trym, UK.

Abstract

The AmbOx trial provides RCT evidence for ambulatory oxygen therapy improving HRQoL in patients with fibrotic ILD http://ow.ly/uHC030nEzsz.